Core Viewpoint - The acquisition of a 1.05% stake in Valgen Holding Corporation by Broncus China Holding Corporation for $15 million (approximately HKD 117 million) is seen as a strategic move to enhance the company's capabilities in comprehensive diagnosis and treatment of cardiopulmonary diseases [1]. Group 1: Acquisition Details - Broncus China Holding Corporation, a wholly-owned subsidiary of the company, has entered into a share transfer agreement with Qi Ming Medical (Hong Kong) Limited to acquire shares in Valgen Holding Corporation [1]. - The total consideration for the acquisition is $15 million, equivalent to approximately HKD 117 million [1]. - Valgen Holding Corporation is registered in the Cayman Islands and focuses on providing systemic solutions for mitral and tricuspid regurgitation diseases [1]. Group 2: Strategic Rationale - The board believes that the acquisition presents a valuable opportunity to achieve a comprehensive diagnosis and treatment platform for cardiopulmonary diseases [1]. - The company's expertise in chronic obstructive pulmonary disease (COPD) will complement the target group's offerings, facilitating the establishment of a robust foundation for integrated cardiopulmonary disease management [1].
堃博医疗-B(02216.HK)附属拟收购1.05% Valgen股份 作价1500万美元